Fate Therapeutics And BD Biosciences Launch BD™ SMC4 To Improve Cellular Reprogramming And IPS Cell Culture Applications
SAN DIEGO, June 11, 2012 /PRNewswire/ — Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced …